Enhanced outcoupling in down-conversion white organic light-emitting diodes using imprinted microlens array films with breath figure patterns.

We demonstrate high-performance down-conversion microlens array (DC-MLA) films for white organic light-emitting diodes (OLEDs). The DC-MLA films are readily fabricated by an imprinting method based on breath figure patterns, which are directly formed on the polymer substrate with a novel concept. The DC-MLA films result in high-quality white light as well as enhanced light outcoupling efficiency for white OLEDs.

Stable angular emission spectra in white organic light-emitting diodes using graphene/PEDOT:PSS composite electrode.

In this work, we suggest a graphene/ poly (3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) composite as a transparent electrode for stabilizing white emission of organic light-emitting diodes (OLEDs). Graphene/PEDOT:PSS composite electrodes have increased reflectance when compared to graphene itself, but their reflectance is still lower than that of ITO itself. Changes in the reflectance of the composite electrode have the advantage of suppressing the angular spectral distortion of white emission OLEDs and achieving an efficiency of 16.

Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.

Objective: The current trial attempted to evaluate the efficacy and toxicity of a salvage therapy consisting of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide for acute leukemia patients in refractory or relapsed states.

Methods: A total of 51 patients with refractory or relapsed acute leukemia were included in the current trial. Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC.

Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.

Introduction: Approximately 45% of adults with acute myeloid leukemia (AML) have normal karyotypes and therefore lack structural abnormalities that can assist in the localization and characterization of molecular defects. The current study attempted to evaluate the potential prognostic role of multidrug resistance (MDR), regarded as one of the potential prognostic factors for the outcome of overall AML, for AML with normal karyotypes.

Method And Materials: A functional MDR assay was performed in pretreatment samples from AML patients with normal karyotypes.

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.

Objectives: A phase II study was conducted to evaluate the response rate and safety of a combination regimen of docetaxel plus capecitabine in patients with advanced gastric cancer.

Patients And Methods: Patients with previously untreated metastatic or recurrent measurable gastric cancer received i.v.

Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass.

A malignant peripheral nerve sheath tumor (MPNST) is an extremely rare soft tissue tumor in the general population. On the other hand, there is a higher incidence of MPNST in patients with neurofibromatosis type I (von Recklinghausen's disease). The common sites are the extremities, trunk, head and neck.

Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.

In addition to the clinical disease status at transplantation, the cytogenetic risk at presentation also provides critical information for predicting the prognosis or deciding the future therapeutic strategy. As such, the current study examined various parameters, including the cytogenetics at presentation and clinical disease status at transplantation, regarding their effect on the transplant outcomes of acute myeloid leukemia (AML) patients in an allogeneic peripheral blood stem cell transplantation (PBSCT) setting. A total of 36 patients receiving an allogeneic PBSCT from matched sibling donors were included in a state of first complete remission (CR) (n=22, 61%) or beyond the first CR (n=14, 39%).

Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.

Although the use of peripheral blood stem cells instead of bone marrow is still a matter of debate in transplantation from HLA-identical sibling donors, allogeneic peripheral blood stem cell transplantation (PBSCT), with a stronger graft-versus-leukemia (GVL) effect, may be preferable as a source of stem cells, especially in the case of advanced hematologic diseases. As such, the current paper reports on the outcomes of 27 consecutive patients with high-risk hematologic diseases treated with allogeneic PBSCT. The median dose of CD34+, CD3+ cells, and MNC infused was 8.

Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation.

The role of repopulating lymphocytes after allogeneic stem cell transplantation (SCT) includes the prevention of serious infections and attacking residual tumour cells in the early post-transplant phase. Therefore, the current study analysed the role of the absolute lymphocyte count (ALC) on day 21 after SCT in predicting transplant outcomes of 82 patients in terms of the risk of opportunistic infections and recurrence of original disease. The median dose of CD34+, CD3+ and mononuclear cells (MNC) infused was 6.

Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization.

A pilot study was conducted to evaluate the efficacy of harvesting peripheral blood stem cells from normal healthy donors on day 4 after mobilization with G-CSF at 10 microg/kg for 4 days or a sequential combination of GM-CSF at 10 microg/kg for 2 days and G-CSF at 10 microg/kg for 2 more days. Harvesting over the target dose (>4 x 10(6) kg) of CD34+ cells based on the lst leukapheresis performed on day 4 was possible from 7 (53.8%) out of 13 donors.